Clinical Trials Browser

Active not recruiting × Recurrent Squamous Cell Lung Carcinoma × Ipilimumab × Clear all

NCT02785952 2025-05-21

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Phase 3 Active not recruiting

275 enrolled 15 charts

Recurrent Squamous Cell Lung Carcinoma